More about: Antivirals – which? when? how?

POSTVIRAL FATIGUE – AN UPDATE ON DIAGNOSIS AND MANAGEMENT

STEVE ANDREWS
MB ChB, MCFP (SA)
Private Practitioner
Rondebosch
Cape Town

Postviral fatigue (syndrome) is a common disorder characterised by debilitating fatigue and a plethora of neurophysical symptoms and immunological manifestations. The disorder, if it is indeed a single entity, has been recognised throughout history, and known by many names. Spracklen has documented the history of the syndrome.

History of postviral fatigue syndrome
‘The vapours’
Neurasthenia
‘Effort syndrome’
Hyperventilation syndrome
Epidemic neurochemical sensitivity syndrome
Chronic Epstein-Barr virus syndrome
Postviral fatigue syndrome
‘Yuppie flu’
Myalgic encephalomyelitis
Hypoglycaemia

The syndrome has been recognised as an entity, and several attempts have been made by expert task groups to define guidelines for its diagnosis and management. These have been plagued by the multiple and differing presentations of the illness, as well as the very real but not always present or individually alike alterations in physical functioning and immunological malfunctioning. In order to reach some consensus, most experts, as well as sufferer groups, prefer the designation chronic fatigue syndrome (CFS), or chronic fatigue and immune dysfunction syndrome (CFIDS). The Centers for Disease Control (CDC) have set out criteria for CFS.

CDC criteria for CFS
A case of chronic fatigue syndrome is defined by the presence of:
• Clinically evaluated, unexplained, persistent or relapsing fatigue that is of new or definite onset; is not the result of ongoing exertion; is not alleviated by rest; and results in substantial reduction of previous levels of occupational, educational, social, or personal activities; and
• Four or more of the following symptoms that persist or recur during 6 or more consecutive months of illness and that do not predate the fatigue:
  • self-reported impairment in short-term memory or concentration
  • sore throat
  • tender cervical or axillary nodes
  • muscle pain
  • multijoint pain without redness or swelling
  • headaches of a new pattern or severity
  • unrefreshing sleep
  • post-exertional malaise lasting > 24 hours.

A definite aetiology of this condition still eludes researchers, and it remains largely a diagnosis of exclusion. Although Epstein-Barr virus and Coxsackie B viruses have been implicated in CFS by various studies, no single known virus is consistently associated with CFS and viral investigations are usually fruitless. Changes in immune function have been reported in CFS to a larger degree than in disorders such as major depression. These, however, are neither homogenous nor ubiquitous among CFS sufferers, and do not aid in the diagnosis. This is also true of numerous neuroendocrine dysfunctions found in these patients. Magnetic resonance imaging (MRI) may identify small T2 hyperintense signals in a minority of individuals, but these are neither diagnostic nor prognostic.

Symptoms
Specific symptoms may be grouped as follows:
• Fatigue (100% of patients). Most of these patients remain capable of meeting occupational needs, but at the expense of personal and family commitments.
• Neuropsychiatric manifestations, particularly headaches (85 - 90%).
• Physical symptoms (75 - 80%), such as sore throat, arthralgia, feverishness, tender lymphadenopathy.
• Psychiatric manifestations (65%). Mild to moderate depression is present in 30 - 60% of patients. Much is thought to be reactive to the combination of symptoms as described above, and the limitations placed on personal and family commitments by the fatigue experienced. Other clinicians feel that CFS is primarily psychiatric in...
origin, a view which has been adopted by many lay organisations, particularly the insurance industry.

- Other: a plethora of physical symptoms.

**Patient manifestations**

Characteristically, this disorder affects a previously active individual. It usually manifests initially as an unremarkable flu-like illness or other stressor, which leaves prolonged marked exhaustion and other symptoms in its wake. It does not usually progress, and may resolve completely within 6 months, or have a partial response and, in a minority of patients, no or minimal recovery.

**Characteristically, this disorder affects a previously active individual.**

**Investigations**

As this is a diagnosis of exclusion, it is vital to rule out other causes of the presenting symptom complex. Investigations include:

- full physical examination
- routine laboratory tests (full blood count, erythrocyte sedimentation rate, liver, thyroid and renal function, iron, folate and B12 screen)
- specific laboratory tests guided by physical examination (no specific laboratory test for CFS).

**Treatment**

The mainstay of treatment is symptomatic. Rest is vital, as is the treatment of symptoms with non-steroidal anti-inflammatory drugs and tricyclic antidepressants.

Advice regarding lifestyle alterations (avoidance of heavy meals, moderate intake of stimulants such as caffeine, as well as alcohol and other substances which can aggravate the fatigue) is important.

Some success has been achieved with a carefully graded exercise programme. A comprehensive, empathetic approach, utilising a biopsychosocial approach, is vital in managing this syndrome. Dismissing the reality of symptoms, and moving too quickly to a psychiatric diagnosis (whether primary or secondary), is often at the root of the diagnostic problems experienced by clinicians, and the frustrations expressed by sufferers.

**References**


**INFLUENZA – THE VACCINE IN PRACTICE**

**B D SCHOUB**

MB BCh, MMed, MD, DSc, FRCPA, FCPATH, ISAI, FRSSAf

**Executive Director**

National Institute for Communicable Diseases
Sandringham, Johannesburg

There is little doubt that influenza vaccination in South Africa is seriously underutilised compared with countries in the developed world. In the USA, public health authorities bemoan the fact that the target of the Healthy People 2010 national objectives — 90% influenza vaccine coverage for persons over 65 years of age and 60% for younger adults at higher risk — has not yet been reached (1999 figures were 70% for adults over 65 years and 31% for younger adults at high risk). In South Africa, total influenza vaccine coverage is less than 5% of the population — a major portion of which is accounted for by workforce immunisation of healthy people.

There is in South Africa a much more pervasive apathy and lack of awareness of the benefits of influenza vaccination than in developed countries. Administration of influenza vaccine is good preventive medical practice. It is between 70% and 90% effective, relatively cheap and remarkably safe. Unfortunately however, many unfounded and unsubstantiated myths abound in regard to the influenza vaccine and these need to be debunked by informed health professionals.

‘The vaccine gives me flu, doctor’ is a common patient complaint. Clearly the inactivated or subunit vaccines cannot give influenza. As far as side-effects are concerned, soreness of the arm at the site of injection is a relatively common side-effect but systemic flu-like symptoms are considerably less common. Vaccine side-effects are more common in the elderly, precisely the at-risk group who need to endure some discomfort in order to be protected against a potentially serious illness.

The effectiveness of the vaccine is commonly queried by patients who may experience an upper respiratory tract infection in the winter season subsequent to receiving the vaccine. Here it needs to be emphasised that the vaccine is specific to the influenza virus alone.
and offers no protection against the more ubiquitous common cold viruses. However, it is specifically influenza virus infection which can potentially lead to serious and occasionally lethal complications. On a slightly lighter note, one sometimes gets feedback from general practitioners complaining that administration of the vaccine reduces the number of winter GP consultations! Even general practitioners need to be reassured that they will still see their quota of non-influenza URTI patients, despite the vaccine.

Occupational health doctors are sometimes unconvinced of the cost benefit of annual vaccination of their workforce as some of the earlier literature claimed to demonstrate no cost savings. In more recent publications, however, rigorously controlled studies in very large populations such as health management organisations in the USA, have consistently demonstrated the cost benefit of annual immunisation of workers to reduce absenteeism. Naturally the benefits will be less so in those years with quiet influenza seasons. Unfortunately however, there are no tools to predict the severity of influenza in a future season.

Some people have expressed the opinion that it may be preferable to get the natural infection where the immunity is known to be more durable than that from the vaccine. In reality, influenza vaccine does not prevent infection with the virus as demonstrated by the fact that the repertoire and level of antibodies in those who are regularly vaccinated is no different from those who have never been vaccinated. What the vaccine does is to prevent the illness due to the virus.

When April or May comes about there is also a common feeling that the ‘boat has been missed’ and that there is no longer any point in being vaccinated. Nothing could be further from the truth. Influenza outbreaks in southern Africa usually commence in June and July, although the actual onsets are unpredictable. Immunity takes from 10 to 14 days to develop after vaccination and it is therefore preferable to vaccinate close to the winter season, so that antibody levels are still high when the annual outbreak starts. This should be balanced against vaccinating too late, and being unprepared for the outbreak, especially if this occurs early. It is however never too late to vaccinate, bearing in mind that it takes 10 to 14 days for a protective immune response to commence.

Lastly, practitioners are frequently faced with fit and tanned septuagenarians who stoutly maintain that they have never had flu or a cold in their lives and have no need for the influenza vaccine. However these are precisely the individuals who really need to be persuaded about their vulnerability to influenza complications and the efficacy and safety of influenza vaccines.

HIV shares routes of transmission with the chronic hepatitis viruses B and C. All three can be transmitted by blood products or needle sharing in intravenous drug users. HIV and hepatitis B can also be transmitted sexually and vertically (hepatitis C is seldom transmitted by these routes). Therefore it is not surprising that co-infection with HIV and hepatitis B or C is common. Co-infection particularly affects hepatitis virus infections. There appears to be no effect of either hepatitis B or C on the natural history of HIV, but co-infection complicates the use of highly active antiretroviral therapy (HAART). Complications of chronic viral hepatitis have emerged as leading causes of morbidity and mortality in HIV-infected patients in regions where there is ready access to HAART. Medical therapy of chronic hepatitis B and C is complex and expensive, and should be undertaken only by specialists in the field.

**Hepatitis B and HIV**

It is estimated that there are 350 000 000 chronic carriers of hepatitis B worldwide. Sub-Saharan Africa and South East Asia are the two geographical areas most affected. These are also the areas with the highest HIV burden. In the USA the two main groups with significant HIV prevalence are intravenous drug users and men...
who have sex with men — these same groups have hepatitis B carrier rates 5 - 20 times higher than those in the general population. Therefore co-infection with HIV and hepatitis B is very common in all regions.

The main effect of co-infection is to increase the infectiousness of hepatitis B. Hepatitis B viral loads (a measure of viral replication) are higher in HIV-positive patients. In patients who are hepatitis B surface- and e-antigen positive (the main markers of infectiousness), the rate of development of antibodies to surface- and e-antigen (and hence loss of infectiousness) is low. Loss of e-antibody-positive status with the regression to e-antigen-positive status has even been documented in HIV infection.

Paradoxically, in HIV/hepatitis B co-infection there is less hepatic inflammation with lower elevations of transaminases, particularly in patients with lower CD4 lymphocyte counts. This is thought to be because hepatic inflammation is mediated by the immune system rather than a cytopathic effect of hepatitis B. It is unclear whether this lesser degree of hepatic inflammation will result in fewer cases of chronic liver disease caused by hepatitis B, as studies have shown contradictory results.

The initiation of HAART in patients with hepatitis B is associated with a high rate of hepatitis. This is thought to be due to the reconstitution of the immune system, with resulting increased hepatic inflammation. The problem is that this is very difficult to distinguish from hepatotoxicity of antiretroviral drugs. The development of IgM anticore antibody suggests a hepatitis B flare rather than a drug reaction, while eosinophilia or a hypersensitivity rash suggests a drug reaction. It is prudent to avoid antiretroviral drugs with a high rate of hepatotoxicity (e.g. nevirapine) in patients with chronic hepatitis B infection.

Response rates to interferon alfa for hepatitis B are lower in HIV-infected patients, and therapy is not well tolerated. Nevertheless, interferon alfa can be used in selected patients as some patients will convert from e-antigen positive to e-antibody positive. Lamivudine, which is used to treat HIV, has useful activity against hepatitis B. Unfortunately hepatitis B resistance develops at the rate of about 20% per annum in HIV-negative patients and at higher rates in HIV-positive patients. The main role of lamivudine appears to be for patients with decompensated cirrhosis. However, lamivudine is nearly always used in either an initial or subsequent HAART regimen. If lamivudine is discontinued because of HIV virological failure, a flare of hepatitis can ensue. Therefore lamivudine use in co-infected patients should be monitored carefully by serial viral load measurements of both HIV and hepatitis B. It may be prudent not to use lamivudine in the initial regimen unless there is evidence of significant hepatitis B-induced liver disease.

Recently the nucleotide analogues tenofovir and adefovir have shown useful antihepatitis B activity, even when lamivudine resistance has developed. Trials of combination antiviral therapy for hepatitis B are being conducted. Tenofovir is registered for use in HIV infection in many developed countries, but not yet in South Africa.

Hepatitis B vaccination should be considered for HIV-infected patients who are not immune (i.e. antihepatitis B surface-antibody negative), but the response rates to vaccination are lower than in immunocompetent persons, particularly if the CD4+ T lymphocyte count is less than 200 x 10^6/l.

Hepatitis C and HIV

The prevalence of hepatitis C infection in intravenous drug users and haemophiliacs in the USA is 80% or higher. Hepatitis C and HIV share these important HIV transmission routes in developed countries. However, HIV/hepatitis C co-infection is uncommon in South Africa.

There is an increase in the hepatitis C viral loads in HIV-infected patients and progression to cirrhosis is faster in co-infected patients. The current therapy of choice in hepatitis C is interferon alfa (especially long-acting pegylated derivatives) combined with the antiviral drug ribavirin. Response rates appear to be reasonable in HIV-infected patients, but lower than in HIV-negative patients (especially if the CD4 lymphocyte count is low). As with hepatitis B, interferon therapy is not well tolerated by HIV-infected patients. Hepatotoxicity is also increased when HAART is used.

FURTHER READING